Oncology & Cancer

Merck KGaA suffers setback for cancer drug

German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.

Medications

Merck: New drugs pending approval or in late tests

Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.

Medications

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications

Merck completes sale of consumer unit to Bayer

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Medications

Merck sues to challenge new US drug price program

Merck filed a lawsuit Tuesday challenging a new White House-backed program to limit drug prices, calling the initiative an unconstitutional "extortion" that will harm pharmaceutical innovation.

Medications

FDA has safety concerns on Merck insomnia drug

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

page 8 from 14